Celltrion has garnered a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending granting a pan-European marketing authorization for the firm’s Vegzelma (bevacizumab) biosimilar rival to Avastin.
Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod
Vegzelma CT-P16 Biosimilar Rival To Avastin Receives CHMP Positive Opinion
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
